Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Shire
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males and females 18 years of age or older
Must currently be on ACE inhibitor therapy and have received a dose within 36 hours
Presenting with ACEIA of the head/neck region within 12 hours after onset
All females must have a negative urine pregnancy test prior to administration of the study drug. Those who have had a total hysterectomy, bilateral oophorectomy or are two years post-menopausal do not require a pregnancy test.
You may not be if
Hypersensitivity to ecallantide
Pregnancy or breast feeding
Patients who have had angioedema and were not concurrently on an ACE inhibitor
Patients exhibiting urticaria
Patients who are intubated or who have a tracheostomy related to the current episode of angioedema
Opinion of the investigator that the patient would not be a good candidate
Participation in another investigational study within 30 days prior to enrollment
Clareo Health | Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
